title: Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
abstract: Insights into the molecular basis of hormone-refractory prostate cancer have principally relied on human prostate cancer cell lines, all of which were derived from patients who had already failed hormonal therapy. Recent progress in developing genetically engineered mouse prostate cancer models provides an opportunity to isolate novel cell lines from animals never exposed to hormone ablation, avoiding any potential bias conferred by the selective pressure of the castrate environment. Here we report the isolation of such a cell line (Myc-CaP) from a c-myc transgenic mouse with prostate cancer. Myc-CaP cells have an amplified androgen receptor gene despite no prior exposure to androgen withdrawal and they retain androgen-dependent transgene expression as well as androgen-dependent growth in soft agar and in mice. Reexpression of c-Myc from a hormone-independent promoter rescues growth in androgen-depleted agar but not in castrated mice, showing a clear distinction between the molecular requirements for hormone-refractory growth in vitro versus in vivo. Myc-CaP cells represent a unique reagent for dissecting discreet steps in hormone-refractory prostate cancer progression and show the general utility of using genetically engineered mouse models for establishing new prostate cancer cell lines.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of California at Los Angeles, 90095, USA.
authors.forename: Philip A
authors.initials: PA
authors.lastname: Watson
authors.forename: Katharine
authors.initials: K
authors.lastname: Ellwood-Yen
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: King
authors.forename: John
authors.initials: J
authors.lastname: Wongvipat
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Lebeau
authors.forename: Charles L
authors.initials: CL
authors.lastname: Sawyers
mesh_terms: D000728:Androgens / Q000502:physiology*; D000818:Animals; D002369:Castration; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D005818:Genetic Engineering; D006801:Humans; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000502:physiology*; D011944:Receptors, Androgen / Q000378:metabolism*; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000728:Androgens; D016271:Proto-Oncogene Proteins c-myc; D011944:Receptors, Androgen